If you are already a subscriber to this publication click here to read this item online in full.
If you wish to purchase the back-issue in which this item appeared, take a note of the Newsletter title and the month of publication and click here to visit the back-issues page from where you can order it.
Issue: November 2009, page: 7
ReGen continues to back knee implant, while US authority reviews own procedures
ReGen Biologics is continuing to market its collagen meniscus implant, trademarked Menaflex, while the US Food and Drug Administration (FDA) reviews its procedural assessment of the process by which the implant received marketing clearance.